LANGHORNE, PA — NEXGEL, Inc. (Nasdaq: NXGL) recently appointed Ian Blackman as chief financial officer as the company works to complete a planned acquisition of regenerative biomaterial assets from Celularity Inc. (Nasdaq: CELU), the company announced.
Blackman will help advance the closing of a definitive agreement to license and acquire a portfolio of commercial-stage products from Celularity, according to the announcement.
Chief Executive Officer Adam Levy said the appointment comes as the company expands its consumer and healthcare portfolio and prepares for integration of the Celularity assets.
Blackman has more than 30 years of experience in finance, including roles overseeing treasury, tax and operations across private equity-backed and public companies.
He previously served as chief financial officer of McIntosh Group, where the company said he helped increase revenue by more than 90% and EBITDA by more than 335%, and led two sale transactions.
Blackman also held finance leadership roles at Universal Music Group and served as CFO for consumer brands including Diptyque and Trish McEvoy.
Blackman said his focus will include supporting the acquisition process and strengthening financial operations.
“The opportunity to help guide the transaction process, support integration planning, and strengthen the financial foundation of the combined organization is strategically important,” he said.
NEXGEL develops hydrogel-based products used in healthcare and consumer applications, including over-the-counter products and medical materials.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.